

## **Department of Planning and Budget**

### **2016 Fiscal Impact Statement**

**1. Bill Number:** SB701ER

<b>House of Origin</b>	<input type="checkbox"/> Introduced	<input type="checkbox"/> Substitute	<input type="checkbox"/> Engrossed
<b>Second House</b>	<input type="checkbox"/> In Committee	<input type="checkbox"/> Substitute	<input checked="" type="checkbox"/> Enrolled

**2. Patron:** Marsden

**3. Committee:** Education and Health

**4. Title:** Cannabidiol oil and THC-A oil; permitting of pharmaceutical processors to manufacture and provide.

**5. Summary:** Authorizes a pharmaceutical processor, after obtaining a permit from the Board of Pharmacy and under the supervision of a licensed pharmacist, to manufacture and provide cannabidiol oil and THC-A oil. The bill requires the Board of Pharmacy to adopt regulations establishing health, safety, and security requirements for permitted processors. The bill also requires that a practitioner who issues a written certification for cannabidiol and THC-A oil and the patient or his primary caregiver to register with the Board and requires a permitted pharmaceutical processor, prior to providing the patient or his primary caregiver and the practitioner who issues a written certification have registered with the Board. Finally, the bill provides criminal liability protection for pharmaceutical processors. An enactment clause provides that except for provisions requiring the Board of Pharmacy to promulgate regulations, the provisions of the bill do not become effective unless reenacted by the 2017 Session of the General Assembly.

**6. Budget Amendment Necessary:** No.

**7. Fiscal Impact Estimates:** Indeterminate, see item #8.

**8. Fiscal Implications:** The fiscal impact this bill would have on the Commonwealth cannot be determined at this time. The provisions of the bill would require registration of physicians, patients, or parent or guardian if the patient is a minor or incapacitated adult who are involved in receiving cannabidiol for intractable epilepsy. This would require permitting of a pharmaceutical processor by the Board of Pharmacy. Permitting of these processing facilities would be a departure from the normal scope of activity for the Board and might necessitate a new position to manage this process. However the scope of the permitting and registration is unknown at this time and the agency cannot determine the extent to which a position is needed. The promulgation of regulations should not impact agency operations.

**9. Specific Agency or Political Subdivisions Affected:** Department of Health Professions.

**10. Technical Amendment Necessary:** No.

**11. Other Comments:** None.